Pfizer-BioNTech's vaccine against Covid-19 was 73 percent effective in protecting infants -- ages 6 months to 4 years -- during the period when the Omicron variant of the coronavirus was highly prevalent, pharmaceutical company Pfizer announced Tuesday.
The US Food and Drug Administration (FDA) gave permission on June 17 to administer the vaccine to this age group.
Infants in the study received either three doses (3 µg) of the Pfizer-BioNTech vaccine or a placebo. The vaccine's effectiveness was 73,2% in infants aged 6 months to 4 years, according to results announced by the two drug companies.
"While these results confirm that the three doses of 3 µg of our vaccine against her Covid-19 provided infants with a high level of protection at a time when the Omicron BA.2 subvariant was particularly prevalent, (…) we are also developing a bivalent Omicron BA.4/BA.5 vaccine tailored to this age group to address of these subvariants," said Ugur Sahin, CEO and co-founder of BioNTech.
RES - EAP